Swedish Orphan Biovitrum AB (publ) (Sobi) today announced the appointments of Krassimir Mitchev, MD, Ph.D., and Stefan Lethagen, MD, Ph.D. as two new senior members joining the company`s haemophilia team.
Dr. Mitchev has been appointed Vice President and Medical Therapeutic Area Head, Haemophilia. He earned his medical and doctorate degrees from the University of Sofia in Bulgaria and is specialised in internal and pulmonary medicine. Dr. Mitchev brings more than 25 years of medical and scientific leadership experience from senior roles at GSK and UCB Pharma, and from academic positions at Erasme Hospital in Brussels and at University Hospital Sofia. Most recently he was Medical Director at the Center of Excellence for Immunology and Hepatitis at GSK, where he was responsible for the medical aspects of the Benlysta® launch and for the collaboration with Human Genome Sciences.
"We are pleased to welcome Krassimir to Sobi", said Birgitte Volck, Senior Vice President and Chief Medical Officer at Sobi. "With his strong medical and scientific background as well as leadership experience from the industry including a recent specialty launch and from working in cross-company collaborations to secure patient access for new products, he is ideally suited for the medical leadership role of the Haemophilia programs at Sobi."
Dr. Lethagen has been appointed Vice President Medical and Clinical Sciences, Haemophilia. He received his medical and doctorate degrees from Lund University in Sweden and specialised in internal medicine and haematology at Malmö University Hospital. Dr. Lethagen was appointed Professor in Haemophilia and Thrombosis at the Medical Faculty at Copenhagen University in 2006. He was a founder and Chairman of the Nordic Haemophilia Council from 2007-2009. Stefan joins Sobi from Novo Nordisk, where he served as International Medical Director, Haemophilia, leading early clinical development programs.
"Stefan brings a prominent expertise to his role underlined by his clinical academic credentials and co-authorship of more than 100 peer reviewed publications and several book chapters related to haemophilia", continued Volck. "Krassimir`s and Stefan`s individual and combined expertise will bring important seniority and perspective to Sobi`s haemophilia team as we prepare for the possible launch of the recombinant long-acting haemophilia factors in development with Biogen Idec."
Together with its partner Biogen Idec, Sobi currently has two on-going paediatric phase III trials, KIDS A-LONG and KIDS B-LONG in addition to the on-going open label extension studies from the registrational programmes. Both are on track and Sobi expects to release top line data from these trials during 2014.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (SOBI.ST) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
|For more information - not for publication|
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +46 8 697 20 00|
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE